Introduction
============

Early-stage nasopharyngeal carcinoma (NPC) is traditionally treated with radiotherapy (RT) alone which achieves high overall survival (OS) rates. However, treatment outcome after RT alone in early-stage NPC is not always satisfactory in terms of locoregional control and distant metastasis. Chua et al. \[[@b1-crt-2014-141]\] reported results of 141 early-stage NPC patients treated with RT alone and found that stage II patients showed significantly poorer outcomes. The 10-year disease-specific survival, recurrence-free survival, local control, regional control, and distant control rates of stage I patients were 98%, 94%, 96%, 98%, and 98%, respectively, and the corresponding 10-year survival rates of stage II patients were 60%, 51%, 78%, 93%, and 64%, respectively. In addition, parapharyngeal extension \[[@b2-crt-2014-141],[@b3-crt-2014-141]\], N1 \[[@b1-crt-2014-141],[@b4-crt-2014-141]\] or T2N1 (1992 Fuzhou, China staging system) \[[@b5-crt-2014-141]\] increased the incidence of distant metastasis or were associated with poorer survival in early-stage NPC.

Chemotherapy (CTx) has been used before, during, or after RT in selected early stage NPC at the physician's discretion. Concurrent CTx is considered to improve locoregional control, and Xu et al. \[[@b6-crt-2014-141]\] retrospectively found that the locoregional control rate in T2N1 NPC was significantly higher for concurrent CTx than RT alone (91.5% vs. 77.3%, p=0.008). On the other hand, neoadjuvant CTx has been used to reduce distant metastasis, but results of two studies about the role of neoadjuvant CTx in early-stage NPC were contradictory. Neoadjuvant CTx decreased distant metastasis and improved OS in a subgroup analysis of two randomized trials \[[@b7-crt-2014-141]\], but not in a retrospective study \[[@b8-crt-2014-141]\]. Hence, the role of CTx in early-stage NPC is ill-defined.

To define the roles of neoadjuvant and concurrent CTx on patterns of failure and survival in stage II NPC patients, we retrieved and analyzed the data of stage II NPC patients collected in a database for the patterns of care study conducted by Head and Neck Study Group of the Korean Society for Radiation Oncology (KROG 11-09).

Materials and Methods
=====================

The Institutional Review Boards of all participating hospitals approved this retrospective study and waived the requirement for informed patient consent.

1. Patients
-----------

From 2004 to 2011, 804 patients with nasopharyngeal cancer were treated at 15 hospitals in South Korea, and of these, 138 patients from 12 hospitals met the following study eligibility criteria: biopsy-proven NPC, American Joint Committee on Cancer (AJCC) 2002 stage II (T2N0, T1N1, or T2N1), completion of curative RT, and available information on patterns of failure and survival. Patient and tumor characteristics are listed in [Table 1](#t1-crt-2014-141){ref-type="table"}. Patients with a follow-up period of less than 12 months without any event were excluded.

2. Pretreatment workup
----------------------

All patients underwent computed tomography (CT, n=129) and/or magnetic resonance imaging (MRI, n=104) of the head and neck. For the systemic work-up, bone scan (n=23) and abdominal ultrasonography or CT (n=13) were used. Positron emission tomography-computed tomography (PET-CT) was used in 79.0% of the patients (109/138). After PET-CT became reimbursable by Korean National Health Insurance System in June 2006, it became routine.

3. Treatment
------------

RT techniques included 2-dimensional RT alone (2D-RT) in three patients, 2D-RT followed by 3-dimensional conformal RT (3D-CRT) or intensity-modulated radiation therapy (IMRT) in six, 3D-CRT alone in 50, 3D-CRT followed by stereotactic body RT (SBRT) in one, and IMRT alone in 78. Total dose ranged from 64 to 74.2 Gy (median, 70 Gy), after excluding one patient given 100.2 Gy by 3D-CRT and SBRT. RT was given once daily at a median fraction size of 2.12 Gy (1.8 Gy in 32, 2.0 Gy in 35, 2.12 Gy in 24, 2.20 Gy in 15, 2.25 Gy in 15, and 2.4 Gy in 17).

CTx was used in neoadjuvant, concurrent, and adjuvant settings. Neoadjuvant CTx was used in 17.4% of patients (24/138) and concurrent CTx in 70.3% (97/138). Accordingly, there were four treatment groups: RT alone in 34 patients, neoadjuvant CTx followed by RT alone in seven patients, concurrent chemoradiotherapy (CCRT) in 80 patients, and neoadjuvant CTx followed by CCRT (neo-CCRT) in 17 patients. During RT, most patients were given cisplatin weekly or every 3 to 4 weeks. Cisplatin-based combination regimens were used for neoadjuvant CTx. Neoadjuvant CTx regimens used 5-fluorouracil and cisplatin in 11 patients, docetaxel and cisplatin in six, 5-fluorouracil, docetaxel and cisplatin in four, and other taxane-containing regimens in three. Concurrent CTx regimens were cisplatin every 3 to 4 weeks in 45 patients, weekly cisplatin in 40, 5-fluorouracil and cisplatin in five, and other regimens in seven. Adjuvant CTx was used in 30.4% of the patients (42/138): 39 patients in CCRT group, two in neo-CCRT group, and one in RT alone group. Adjuvant CTx regimens were 5-fluorouracil and cisplatin in 38 patients and taxane-containing regimens in three.

Planned neck dissection was not performed in all patients. Instead, three patients with partial response underwent neck dissection at 37, 48, and 101 days after completing RT. These patients were not considered to have regional recurrence.

4. Statistical analysis
-----------------------

The chi-square test or Fisher exact test and the Student t test or one-way ANOVA were used to evaluate group differences among categorical or continuous variables as appropriate. The duration of locoregional relapse-free survival (LRRFS), distant metastasis-free survival (DMFS), progression-free survival (PFS), and OS rates was calculated from treatment start to the date of the first event or the date of last follow-up. Survival curves were calculated using the Kaplan-Meier method. Log-rank tests and the Cox proportional hazard model using backward stepwise elimination procedure to remove variables with a p-value of ≥ 0.10 were used to determine the prognostic significance of variables. IBM SPSS ver. 22 (IBM Co., Armonk, NY) was used for analysis, and p-values of \< 0.05 were considered significant.

Results
=======

1. Patient and tumor characteristics
------------------------------------

Patient and tumor characteristics, except N stage and the use of adjuvant CTx, were not significantly different between neoadjuvant CTx and concurrent CTx groups ([Table 2](#t2-crt-2014-141){ref-type="table"}). Neoadjuvant CTx was used only in patients with N1 disease (20.5% vs. 0%, p=0.025). Concurrent CTx was used more frequently in patients with N1 disease (75.2% vs. 42.9%, p=0.003). Adjuvant CTx was predominantly used in concurrent CTx group (42.3% vs. 2.4%, p \< 0.001).

2. Patterns of failure and survival
-----------------------------------

Median follow-up in the 138 patients was 48 months (range, 7 to 97 months). Thirty-two patients experienced treatment failure; locoregional failure in 14 (9 local, 4 regional, and 1 locoregional), distant failure in 16, and both in two.

Of the 14 patients with locoregional relapse only, salvage surgery (n=3), RT (n=6), or both (n=1) were applied, and four received additional CTx. One patient was treated with CTx alone. Four patients died at 16, 22, 35, and 45 months after diagnosis of recurrence and eight patients remained alive at 12 to 84 months after recurrence (median, 30 months). OS rate after diagnosis of locoregional recurrence was 63.0% at 3 years. Of the 18 patients with distant metastasis, palliative CTx was administered in 15 patients. The OS rate after diagnosis of distant metastasis was 57.6% at 3 years. At the last follow-up, 13 of the 138 patients had died: nine of distant metastasis, two of local recurrence, one of a non-nasopharyngeal cause, and one of unknown cause.

3. Prognostic factors
---------------------

[Fig. 1](#f1-crt-2014-141){ref-type="fig"} shows survival curves and [Table 3](#t3-crt-2014-141){ref-type="table"} shows the results of univariate and multivariate analyses of prognostic factors. OS rates were 93.7% at 3 years and 88.2% at 5 years. Age and N stage were significant prognostic factors in both univariate and multivariate analysis. However, neither concurrent CTx nor neoadjuvant CTx improved OS.

PFS rates were 77.0% at 3 years and 74.4% at 5 years. Concurrent CTx and N stage were significantly associated with PFS by univariate analysis, but only concurrent CTx was significant in multivariate analysis. [Fig. 2A](#f2-crt-2014-141){ref-type="fig"} shows the PFS curves according to the use of concurrent CTx.

LRRFS rates were 90.5% at 3 years and 86.2% at 5 years. Significant variables were gender, concurrent CTx, and N stage in univariate analysis. Concurrent CTx and N stage were significantly associated with LRRFS in multivariate analysis. Neoadjuvant CTx did not improve locoregional control. [Fig. 2B](#f2-crt-2014-141){ref-type="fig"} shows LRRFS curves according to the use of concurrent CTx: 3- and 5-year LRRFS of each group were 78.8% vs. 95.7% and 66.6% vs. 95.7%, respectively. DMFS rates were 86.8% at 3 years and 85.5% at 5 years. No significant prognostic factor was identified in univariate or univariate analysis.

Discussion
==========

In this study, concurrent CTx significantly improved LRRFS and PFS in stage II stage NPC, whereas neoadjuvant CTx did not. However, neither neoadjuvant nor concurrent CTx reduced distant metastasis or increased OS.

CCRT is a standard treatment for stage III/IV locally advanced NPC due to both locoregional control and survival benefit compared to RT alone. Intergroup Study 0099, in which concurrent (cisplatin) and adjuvant CTx (5-fluorouracil and cisplatin) were used, showed improved PFS and OS \[[@b9-crt-2014-141]\], and randomized clinical trials in endemic areas produced similar results \[[@b10-crt-2014-141]-[@b12-crt-2014-141]\].

Based on these findings, concurrent CTx could be expected to improve locoregional control and survival rates in selected early-stage NPC patients. Cheng et al. \[[@b13-crt-2014-141]\] reported that concurrent CTx (5-fluorouracil and cisplatin) achieved a locoregional control rate of 100% at 3 years in 32 patients with AJCC 1997 stage II NPC, whereas RT alone achieved a locoregional control rate of 91.7% in 12 patients with stage I or II NPC. Xu et al. \[[@b6-crt-2014-141]\] retrospectively compared RT alone with CCRT (cisplatin) in patients with AJCC 2002 T2N1 NPC, and found concurrent CTx significantly improved locoregional control (91.5% vs. 77.3% at 5 years, p=0.008), but not DMFS or OS. In the present study, concurrent CTx significantly improved locoregional control in stage II NPC patients ([Table 3](#t3-crt-2014-141){ref-type="table"}), but this was not reflected by an OS improvement. This discrepancy may have been caused by the effectiveness of salvage treatment, as the majority of patients with locoregional relapse alone were treated with salvage surgery or RT, and 5-year OS of patients with locoregional relapse alone was 42%. However, although a lack of an OS increase mitigates against the use of concurrent CTx, its use seems warranted based on improved locoregional control, since the toxicities related to salvage treatments for locoregional recurrence after RT alone may be greater than the toxicities associated with concurrent CTx. A recent phase III trial showed the benefit of CCRT in NPC patients with Chinese 1992 stage II \[[@b14-crt-2014-141]\], equivalent to AJCC 2010 stage II-III, but only 13% of the study\'s patients were AJCC stage III. Concurrent cisplatin given weekly during RT significantly improved OS (94.5% vs. 85.8% at 5 years, p=0.007) by reducing distant metastasis rather than locoregional failure. However, as the current study showed no difference in DMFS by use of concurrent CTx (85.6% vs. 85.4% at 5 years), and there has not been enough evidence that concurrent CTx can reduce distant metastasis, follow-up data in a large cohort of early stage NPC may be needed to assess the effect of concurrent CTx on distant metastasis.

Conversely, IMRT without any kind of CTx achieves high locoregional control and OS rates. Su et al. \[[@b2-crt-2014-141]\] in a Chinese study reported disease-specific survival, local recurrence-free survival and DMFS rates were 97.3%, 97.7%, and 97.8%, respectively, at 5 years in 198 patients with AJCC 2002 stage I-IIb NPC treated with IMRT without CTx (141 of these patients had stage IIb). Local relapse only occurred in patients with T2b disease and their local recurrence-free survival rate was 94.2% at 5 years. Tham et al. \[[@b15-crt-2014-141]\] reported a 3-year OS of 96.2% in 107 patients, only nine of whom received concurrent CTx, with stage IIb NPC treated with IMRT with or without CTx. However, since most studies favoring IMRT alone were reported from single institutional retrospective experiences in endemic areas, it is unclear whether IMRT alone is sufficient to treat the stage II NPC, especially in non-endemic areas.

Neoadjuvant CTx has been used to reduce distant metastasis in locally advanced NPC. Of five randomized controlled studies using neoadjuvant CTx followed by RT alone, DFS was increased by neoadjuvant CTx only in one study, and OS was not improved in any of the studies \[[@b16-crt-2014-141]-[@b20-crt-2014-141]\]. A meta-analysis also concluded that neoadjuvant CTx does not improve OS \[[@b21-crt-2014-141]\]. Although neoadjuvant CTx is also used in early stage NPC, its effect remains unclear. A pooled analysis of two randomized controlled trials conducted by Chua et al. \[[@b7-crt-2014-141]\] in AJCC 1997 stage I and II NPC revealed that induction CTx (cisplatin, epirubicin, and 5-fluorouracil) improved OS by 12% (79% vs. 67% at 5 years, p=0.048) by reducing distant metastasis (86% vs. 71% at 5 years, p=0.005) in earlystage NPC (T1-2N0-1). However, Song et al. \[[@b8-crt-2014-141]\] reported that induction CTx (cisplatin and 5-fluorouracil) did not improve clinical outcomes including distant metastasis and OS in AJCC 1997 stage I and II NPC. In the current study, 24 patients with AJCC 2002 stage II NPC were treated with neoadjuvant CTx (mainly cisplatin and 5-fluorouracil) followed by RT alone (n=7) or RT combined with concurrent CTx (n=17). Although the number of patients enrolled in the current study was small, neoadjuvant CTx did not improve DMFS or PFS. Tham et al. \[[@b15-crt-2014-141]\] also found that neoadjuvant CTx did not improve DMFS in stage IIB NPC.

In addition, delayed definitive RT and toxicities associated with neoadjuvant CTx could be harmful. Song et al. \[[@b8-crt-2014-141]\] reported that RT delay due to neoadjuvant CTx resulted in poorer locoregional control in stage IIB disease than RT alone (p=0.044). In another trial, in which combination of bleomycin, epirubicin and cisplatin were used, treatment-related death was found to be greater for induction CTx than RT alone (8% vs. 1%) \[[@b17-crt-2014-141]\]. However, when considering that distant metastasis is still problematic in early stage NPC, and earlier studies used old chemotherapeutic regimens, neoadjuvant CTx with novel agents deserves investigation.

Unlikely concurrent and neoadjuvant CTx, the effect of adjuvant CTx on early stage NPC has not been investigated. In locally advanced NPC, adjuvant CTx after RT alone did not improve DFS or OS in three randomized trials \[[@b22-crt-2014-141]-[@b24-crt-2014-141]\]. Instead, adjuvant CTx has been used with CCRT based on the results of randomized trials, which showed that CCRT followed by adjuvant CTx significantly improved OS compared to RT alone \[[@b9-crt-2014-141]-[@b11-crt-2014-141]\]. Cheng et al. \[[@b13-crt-2014-141]\] also used adjuvant CTx following CCRT in 32 stage II NPC patients, but could not investigate the effects of adjuvant CTx due to the low incidence of distant metastasis. In the present study, adjuvant CTx was used mainly in the CCRT group, but although it was used in 47.6% of patients in this group, it did not appear to improve PFS or OS (data not shown). Hence, the efficacy of adjuvant CTx in early stage NPC remains unclear.

This study is inherently limited by its retrospective nature. Another limitation is the change of the staging system: stage II in the AJCC 2002 staging system consists of IIa (T2aN0) and IIb (T1N1, T2bN0, T2a/bN1), but T2aN0 was moved to stage I in AJCC 2010 staging system \[[@b25-crt-2014-141]\]. T2a and T2b disease could not be analyzed separately because of the lack of information. Epstein-Barr virus infection was tested in only 37 of 138 patients (26.8%), in whom the positive rate was 75.7% (28/37). A variety of CTx regimens and RT techniques were used.

However, this study also has some strengths. Because it was a multi-institutional study, retrospective bias was probably reduced. In addition, because the quality of oncologic management, including imaging techniques, CTx, and RT, has improved significantly, we included only patients treated during the last decade. MRI was used in 75.4% of patients for staging, which can discriminate T stage more than CT. PET-CT was used in 79.0% of patients as an initial systemic work-up tool, which means that the risk of including patients with asymptomatic distant metastasis was lower than other studies. In addition, since PET-CT was reimbursed by national health insurance beginning June 2006 and used for routine workups thereafter, locoregional or distant failures were probably detected and treated earlier, which might have influenced PFS and OS.

Conclusion
==========

In summary, concurrent CTx significantly improved LRRFS and PFS in stage II NPC, whereas neoadjuvant CTx did not. These findings need to be confirmed by a randomized clinical trial. Furthermore, since distant metastasis occurred in 13% of patients and was not reduced by adding CTx, more effective novel agents are required.
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###### 

Patients and tumor characteristics

  Characteristic       No. (%)            
  -------------------- ------------------ ------------
  Age (yr)             ≤ 60               99 (71.7)
                       \> 60              39 (28.3)
  Gender               Female             40 (29.0)
                       Male               98 (71.0)
  ECOG                 0                  31 (22.5)
                       1                  95 (68.8)
                       2                  5 (3.6)
                       Unknown            7 (5.1)
  Smoking              No                 69 (50.0)
                       Yes                58 (42.0)
                       Unknown            11 (8.0)
  Histology            WHO 1              19 (13.8)
                       WHO 2              39 (28.3)
                       WHO 3              80 (58.0)
  Histology            Keratinizing       19 (13.8)
                       Non-keratinizing   119 (86.2)
  Epstein-Barr virus   Negative           9 (6.5)
                       Positive           28 (20.3)
                       Unknown            101 (73.2)
  T stage              1                  68 (49.3)
                       2                  70 (50.7)
  N stage              0                  21 (15.2)
                       1                  117 (84.8)
  TNM stage            T1N1               68 (49.3)
                       T2N0               21 (15.2)
                       T2N1               49 (35.5)

ECOG, Eastern Cooperative Oncology Group; WHO, World Health Organization.

###### 

Comparison of patient and tumor characteristics

  Characteristic    Neoadjuvant CTx    Concurrent CTx                          
  ----------------- ------------------ ---------------- ---- ------- ---- ---- ----------
  Age (yr)          ≤ 60               80               19   0.374   27   72   0.318
                    \> 60              34               5            14   25   
  Gender            Male               79               19   0.333   31   67   0.439
                    Female             35               5            10   30   
  Histology         Keratinizing       18               1    0.196   4    15   0.374
                    Non-keratinizing   96               23           37   82   
  T stage           1                  56               12   0.938   18   50   0.412
                    2                  58               12           23   47   
  N stage           0                  21               0    0.025   12   9    0.003
                    1                  93               24           29   88   
  TNM stage         T1N1               56               12   0.030   18   50   0.010
                    T2N0               21               0            12   9    
                    T2N1               37               12           11   38   
  Neoadjuvant CTx   No                 \-               \-   \-      34   80   0.949
                    Yes                \-               \-           7    17   
  Concurrent CTx    No                 34               7    0.949   \-   \-   \-
                    yes                80               17           \-   \-   
  Adjuvant CTx      No                 74               22   0.010   40   56   \< 0.001
                    yes                40               2            1    41   
  RT technique      2D-RT              6                3    0.190   4    5    0.450
                    3D-CRT or IMRT     108              21           37   92   

CTx, chemotherapy; RT, radiotherapy; 2D-RT, 2-dimensional radiotherapy; 3D-CRT, 3-dimensional conformal radiotherapy; IMRT, intensity-modulated radiation therapy.

###### 

Univariate and multivariate analyses of prognostic factors for survival endpoints

  Variable                                        Locoregional relapse-free   Distant metastasis-free   Progression-free   Overall                           
  ----------------------------------------------- --------------------------- ------------------------- ------------------ --------- ------- ------- ------- -------
  Age (≤ 60 yr vs. \> 60 yr)                      0.111                       \-                        0.495              \-        0.150   \-      0.014   0.041
  Gender (male vs. female)                        0.042                       0.087                     0.766              \-        0.268   \-      0.548   \-
  Histology (keratinizing vs. non-keratinizing)   0.936                       \-                        0.721              \-        0.862   \-      0.605   \-
  Neoadjuvant chemotherapy (no vs. yes)           0.477                       \-                        0.453              \-        0.365   \-      0.717   \-
  Concurrent chemotherapy (no vs. yes)            \< 0.001                    0.004                     0.765              \-        0.007   0.012   0.256   \-
  T stage (T1 vs. T2)                             0.243                       \-                        0.163              0.172     0.056   0.077   0.155   \-
  N stage (N0 vs. N1)                             0.002                       0.039                     0.757              \-        0.041   \-      0.007   0.029
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